Author/Authors :
Matsuyama، Koki نويسنده Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan , , Tanaka، Hiroshi نويسنده , , Ota، Takeshi نويسنده Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan , , Baba، Junko نويسنده , , Miyabayashi، Takao نويسنده Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan , , Watanabe، Satoshi نويسنده , , Hiroshi، Hiroshi نويسنده Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan , , Narita، Ichiei نويسنده Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan , , Nakata، Koh نويسنده Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan , , Yoshizawa، Hirohisa نويسنده Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan ,
Abstract :
Background: Nonmyeloablative chemotherapy followed by adoptive
immunotherapy is an attractive strategy for depleting regulatory T cells in the host.
However, its efficacy is transient. Here, we aim to investigate whether cyclic chemoim-
munotherapy has therapeutic efficacy against cancer.
Methods:We examined the efficacy of cyclic chemoimmunotherapy with cyclophos-
phamide and adoptively transferred effector T cells against 5-day, established MCA205
murine skin sarcomas.
Results: Cyclophosphamide administration followed by adoptive immunotherapy
augmented the trafficking of effector T cells into established tumors. Further, multiple
cyclophosphamide administrations helped effector T cells to persist at the sites.
Chemoimmunotherapy achieved complete tumor regression even with the transfer of
a limited number of effector T cells (5×106).
Conclusion: Cyclic chemoimmunotherapy, which maintains adoptively transferred
T cells by impairing regulatory T cells, is a potentially suitable treatment for established
tumors.
